Aduro Biotech — Merger or Acquisition (June 2020)
14 slides from Aduro Biotech's merger presentation, Jun 2, 2020
Slide 1: Chinook Therapeutics: Precision Medicines for Kidney Diseases
Chinook Therapeutics Precision Medicines for Kidney Diseases
Slide 2: Note Regarding Forward-Looking Statements
Note Regarding Forward-Looking Statements This presentation contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify these statements by forward-looking words such as “may,” “will,” “contin
Slide 3: Why are Chinook and Aduro Merging?
Why are Chinook and Aduro Merging? Chinook is focused on developing precision medicines for kidney disease with teams based in Vancouver BC and Seattle WA. Merging with Aduro allows us to accelerate building an industry-leading kidney disease company with: A combined pipeline with 3 clinical program
Slide 4: The Time is Now for Kidney Disease Drug Development
The Time is Now for Kidney Disease Drug Development Emerging patient stratification approaches and translational platforms Causal mutations, biomarkers, single-cell sequencing, organoid / podocyte systems Underserved market with >$100B of annual healthcare costs in U.S. Few new drugs approved in pas
Slide 5: Developing Precision Medicines for Kidney Disease
Developing Precision Medicines for Kidney Disease Chinook’s pipeline is driven by deep insights into disease biology and focused on indications with validated pathways and rapid development opportunities Atrasentan: Phase 3 asset in glomerular diseases Recently in-licensed from AbbVie Well-character
Slide 6: Building a Robust, Diversified Pipeline
Building a Robust, Diversified Pipeline Program Indication Target Validation Lead Optimization IND-Enabling Phase 1 Phase 2 Phase 3 Atrasentan IgA Nephropathy (IgAN) Basket of glomerular diseases CHK-336 Ultra-rare kidney disease Research Programs Other rare, severe chronic kidney diseases including
Slide 7: Experienced Leadership Team
Experienced Leadership Team ~35 FTEs including leaders in chemistry, biology, DMPK, translational medicine, clinical development, regulatory, CMC and G&A Executive Team Current Board Jerel Davis, PhD Paul Eisenberg, MD Srini Akkaraju, MD, PhD Jeremy Caldwell, PhD Eric Dobmeier Preston Klassen, MD, M
Slide 8: Our Vision – Past, Present, and Future
Our Vision – Past, Present, and Future Guiding R&D Principles: Focus on key pathways in kidney disease Design novel, target and differentiated molecules Utilize new and efficient translational approaches to speed R&D Execute clinical trials in defined patient populations with surrogate endpoints 202
Slide 9: What Happens Next?
What Happens Next? Deal has been signed and is expected to close second half of 2020 During the period between sign and close, the two organizations operate as independent companies Management will be working through key decisions and workstreams to ensure that the new organization gets off to a smo
Slide 10: Chinook's Intentions
Chinook’s Intentions We are excited to move the 1301 program forward and hope to retain a well-resourced program and study team Maintain current titles, and salaries Keep reporting structures intact where possible Aduro insured benefits will remain in place until benefits renewal Q1 2021, at which p
Slide 11: What does this mean for other Aduro employees?
What does this mean for other Aduro employees? Aduro employees who are in the G&A group or currently focused on 1301 will have continued employment at time of close For some employees, this will be a transitional assignment, at the end of which they will be eligible for severance benefits under the
Slide 12: Next Steps
Next Steps Interim period while final details of the deal are worked through Chinook team will work closely with Aduro leaders to answer key questions and map out integration plans Q&A sessions will be conducted via video conference for Aduro employees at least weekly We won't have all the answers b
Slide 13: Important Additional Information and Where to Find It
Important Additional Information and Where to Find It This communication contains information in respect of the proposed merger involving Aduro Biotech, Inc. and Chinook Therapeutics U.S., Inc. Aduro plans to file with the Securities and Exchange Commission (the “SEC”) a current report on Form 8-K,
Slide 14: Participants in the Solicitation
Participants in the Solicitation This communication does not constitute a solicitation of proxy, an offer to purchase or a solicitation of an offer to sell any securities. Aduro and Chinook, and each of their respective directors, executive officers and certain employees may be deemed to be particip